3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Withdrawn
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
2
Invasive Pulmonary Aspergillosis
1
Interventions
Cytarabine
81
Azacitidine
66
venetoclax
55
fludarabine
34
fludarabine phosphate
31
Decitabine
28
Cyclophosphamide
28
Idarubicin
24
Peripheral Blood Stem Cell Transplantation
22
Filgrastim
20
Granulocyte Colony-Stimulating Factor
18
Busulfan
18
Mitoxantrone
16
Etoposide
16
Whole-Body Irradiation
15
Mycophenolic Acid
14
Cyclosporine
14
Tacrolimus
13
Melphalan
13
Daunorubicin
13
Clofarabine
13
Methotrexate
12
gilteritinib
11
aldesleukin
11
plerixafor
10
Injections
10
decitabine and cedazuridine drug combination
9
Gemtuzumab
9
Cladribine
9
quizartinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Myeloid, Acute
×
olorofim
×
Clear all
NCT02856178
2018-02-15
SAFEGUARD
F2G Biotech GmbH
Phase 1/2
Withdrawn
NCT03036046
2018-02-15
SAFEGUARDFP
F2G Biotech GmbH
Phase 1/2
Withdrawn